Canurta.ethThe Satoshi Trials™: A Bitcoin Treasury Reserve Thesis
Date of Original Draft: Dec 15, 2024. Special Note: The initial Bitcoin price considered for these calculations is $100,000 USD per BTC given we [had on Dec 15th, 2024] passed the psychological price benchmark. Setting the Stage for Disruption Biotechnology has long grappled with the high costs and uncertainty of drug development, leaving promising therapies for diseases like ALS underfunded. At Canurta, we recognize the need for a transformative approach—one that not only addresses these cha...
Canurta.ethThe Canurta White Paper: Grounds for Further Investigation into Hemp Polyphenols
Written by Akeem Gardner, LLB Originally published on September 28, 2021 in Canurta’s Journal A quick note from Akeem before we begin: “2021 was an amazing year. From the launch of our company we grew by acquiring additional IP and investors who are supporting our mission to heal the world with novel polyphenols that have never been clinically explored before. Our team has shown so much growth in our journey of discovery and learning, and it’s now time to implement our DeSci strategy for our ...
Canurta.ethBuilt to Last, Not to Flex
A Founder's Note — Akeem Gardner"Thus, the deluded Bankrupt raves; Puts all upon a desprate Bet; Then plunges in the Southern Waves; Dipt over Head and Ears—in Debt."Life has a unique way of guiding us exactly where we need to be, often without us fully realizing it at the time. My journey led me to study law at the University of Kent, Canterbury, a path seemingly unrelated to my core passion—innovation and entrepreneurship. Yet, it was precisely in my Company Law class in October 2015 w...
an emerging biotech company using rare hemp polyphenols and DeSci to create safe and effective natural therapeutics
Canurta.ethThe Satoshi Trials™: A Bitcoin Treasury Reserve Thesis
Date of Original Draft: Dec 15, 2024. Special Note: The initial Bitcoin price considered for these calculations is $100,000 USD per BTC given we [had on Dec 15th, 2024] passed the psychological price benchmark. Setting the Stage for Disruption Biotechnology has long grappled with the high costs and uncertainty of drug development, leaving promising therapies for diseases like ALS underfunded. At Canurta, we recognize the need for a transformative approach—one that not only addresses these cha...
Canurta.ethThe Canurta White Paper: Grounds for Further Investigation into Hemp Polyphenols
Written by Akeem Gardner, LLB Originally published on September 28, 2021 in Canurta’s Journal A quick note from Akeem before we begin: “2021 was an amazing year. From the launch of our company we grew by acquiring additional IP and investors who are supporting our mission to heal the world with novel polyphenols that have never been clinically explored before. Our team has shown so much growth in our journey of discovery and learning, and it’s now time to implement our DeSci strategy for our ...
Canurta.ethBuilt to Last, Not to Flex
A Founder's Note — Akeem Gardner"Thus, the deluded Bankrupt raves; Puts all upon a desprate Bet; Then plunges in the Southern Waves; Dipt over Head and Ears—in Debt."Life has a unique way of guiding us exactly where we need to be, often without us fully realizing it at the time. My journey led me to study law at the University of Kent, Canterbury, a path seemingly unrelated to my core passion—innovation and entrepreneurship. Yet, it was precisely in my Company Law class in October 2015 w...
an emerging biotech company using rare hemp polyphenols and DeSci to create safe and effective natural therapeutics
Subscribe to Canurta.eth
Subscribe to Canurta.eth
Share Dialog
Share Dialog
<100 subscribers
<100 subscribers
By Akeem Gardner, CEO & Founder, Canurta Therapeutics
At Canurta, we’ve never followed convention for convention’s sake. We’re building a new blueprint for how biotech companies can scale — one that prioritizes financial resilience, founder-led execution, and long-term shareholder value. That’s why we’re anchoring our capital strategy to Bitcoin.
This is not a gimmick. It’s a deliberate financial move that increases our purchasing and R&D power by 30–60% ARR and positions us to lead institutional biotech innovation in Canada with asymmetric upside and limited downside. We're creating the first adaptive medicine company backed by Bitcoin reserves — and with it, a new playbook for the capital markets.
Strengthens Capital Efficiency
By integrating Bitcoin into our treasury model:
We gain exposure to an appreciating reserve asset
We minimize dilution by accessing BTC-backed financing tools
We enable strategic rebalancing to meet investor needs during volatility
Enables Optionality Without Fragility
With regulated Canadian OTC access and margin lending partners, we can:
Sell or collateralize BTC as needed, without relying on banks
Fund trials, operations, or acquisitions with non-dilutive capital
Maintain a steady NAV anchor (3:1) to issue optional securities if desired
Aligns with Institutional Trends
With FASB guidance and growing institutional adoption, BTC is no longer fringe — it’s part of the future. This gives Canurta a chance to front-run a shift in capital formation and stand out as an institutional-grade biotech that operates with the prudence of a sovereign investor.
As Warren Buffett said:
“Risk is not volatility, but permanent loss of capital.”
We agree. Volatility is not the enemy — poor execution is.
Bitcoin offers volatility, yes — but also resilience, transparency, and global liquidity. By contrast, the permanent loss of purchasing power in fiat currencies, especially the USD, is the silent risk that most overlook.
Executing a strategy like this requires:
Courage from the founder
Goodwill from the team
Trust from our investors
And most importantly: results. We're not asking to be believed — we're asking to be measured. Canurta’s team is here to execute.
Our ambition goes beyond Canurta. We believe Canada can be a global leader in BTC-backed biotech finance. We're building this strategy not just for ourselves, but for:
CanadianMunicipalities, like Vancouver, with forward-thinking financial structures
Corporations and SMEs looking to access resilient, modern capital
Boards of Trade and innovation councils who can champion resilient business models across the country
This isn’t theory — it’s a testable, repeatable path. One step at a time, using open-source tools, transparency, and results.
Bitcoin gives us what traditional portfolios struggle to find: An uncorrelated asset that improves risk-adjusted returns.
We manage volatility through:
Position sizing and drawdown strategies
Keeping our mind on long time horizons that allow us to ride macro cycles
Quarterly rebalancing and capital rotation discipline
Markets reward clarity and courage.We’re not chasing trends — we’re setting the terms.
BTC gives Canurta the freedom to execute without surrendering control. It strengthens our balance sheet, hedges systemic risk, and creates a durable advantage for our shareholders — one that compounds over time.
We're not here to play defense. We're here to win.
Let’s build the future of medicine — backed by the future of money.
Akeem Gardner | CEO & Founder | Canurta Therapeutics | akeem@canurta.com
By Akeem Gardner, CEO & Founder, Canurta Therapeutics
At Canurta, we’ve never followed convention for convention’s sake. We’re building a new blueprint for how biotech companies can scale — one that prioritizes financial resilience, founder-led execution, and long-term shareholder value. That’s why we’re anchoring our capital strategy to Bitcoin.
This is not a gimmick. It’s a deliberate financial move that increases our purchasing and R&D power by 30–60% ARR and positions us to lead institutional biotech innovation in Canada with asymmetric upside and limited downside. We're creating the first adaptive medicine company backed by Bitcoin reserves — and with it, a new playbook for the capital markets.
Strengthens Capital Efficiency
By integrating Bitcoin into our treasury model:
We gain exposure to an appreciating reserve asset
We minimize dilution by accessing BTC-backed financing tools
We enable strategic rebalancing to meet investor needs during volatility
Enables Optionality Without Fragility
With regulated Canadian OTC access and margin lending partners, we can:
Sell or collateralize BTC as needed, without relying on banks
Fund trials, operations, or acquisitions with non-dilutive capital
Maintain a steady NAV anchor (3:1) to issue optional securities if desired
Aligns with Institutional Trends
With FASB guidance and growing institutional adoption, BTC is no longer fringe — it’s part of the future. This gives Canurta a chance to front-run a shift in capital formation and stand out as an institutional-grade biotech that operates with the prudence of a sovereign investor.
As Warren Buffett said:
“Risk is not volatility, but permanent loss of capital.”
We agree. Volatility is not the enemy — poor execution is.
Bitcoin offers volatility, yes — but also resilience, transparency, and global liquidity. By contrast, the permanent loss of purchasing power in fiat currencies, especially the USD, is the silent risk that most overlook.
Executing a strategy like this requires:
Courage from the founder
Goodwill from the team
Trust from our investors
And most importantly: results. We're not asking to be believed — we're asking to be measured. Canurta’s team is here to execute.
Our ambition goes beyond Canurta. We believe Canada can be a global leader in BTC-backed biotech finance. We're building this strategy not just for ourselves, but for:
CanadianMunicipalities, like Vancouver, with forward-thinking financial structures
Corporations and SMEs looking to access resilient, modern capital
Boards of Trade and innovation councils who can champion resilient business models across the country
This isn’t theory — it’s a testable, repeatable path. One step at a time, using open-source tools, transparency, and results.
Bitcoin gives us what traditional portfolios struggle to find: An uncorrelated asset that improves risk-adjusted returns.
We manage volatility through:
Position sizing and drawdown strategies
Keeping our mind on long time horizons that allow us to ride macro cycles
Quarterly rebalancing and capital rotation discipline
Markets reward clarity and courage.We’re not chasing trends — we’re setting the terms.
BTC gives Canurta the freedom to execute without surrendering control. It strengthens our balance sheet, hedges systemic risk, and creates a durable advantage for our shareholders — one that compounds over time.
We're not here to play defense. We're here to win.
Let’s build the future of medicine — backed by the future of money.
Akeem Gardner | CEO & Founder | Canurta Therapeutics | akeem@canurta.com
No activity yet